We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Assessment of neurocognitive decline in cancer patients, except brain cancer, under long-term treatment with bevacizumab.
- Authors
Panciroli, C.; Lucente, G.; Vidal, L.; Carcereny, E.; Quiroga, V.; Pardo, J. C.; Romeo, M.; Estival, A.; Manzano, J. L.; Pardo, B.; Velarde, J. M.; Esteve, A. M.; Lopez, D.; Mañes, A.; Tuset, V.; Villà, S.; Quintero, C. B.
- Abstract
Purpose: We performed a cross-sectional study of neurocognitive function in non-brain cancer patients treated with long-term bevacizumab. Methods/patients: From 2015 to 2017, we included patients with different types of cancer treated with bevacizumab with or without chemotherapy (BEV; N = 20) or only chemotherapy (ChT; N = 19) for at least 34 weeks, patients who received non-brain radiotherapy (RxT; N = 19), and healthy controls (HC; N = 19) were assessed once at week 34 of treatment (BEV and ChT) or at completion of radiotherapy. Neurocognition was evaluated with the Hopkins Verbal Learning Test-Revised (HVLT-R) total and delayed recall, the Trail Making Test A and B, and the Controlled Oral Word Association Test in the four groups. Non-parametric tests were used to assess differences between groups. Results: The BEV, ChT, and RxT groups scored significantly lower than the HC group on all tests and especially on the HVLT-R total recall. In no case were the mean scores of the BEV group significantly lower than those of the ChT or RxT groups. Conclusions: Neurocognitive impairment was seen even in patients treated with local non-brain radiotherapy. Treatment with bevacizumab for a long period of time does not seem to worsen neurocognitive function to a greater extent than chemotherapy.
- Publication
Clinical & Translational Oncology, 2020, Vol 22, Issue 3, p411
- ISSN
1699-048X
- Publication type
Article
- DOI
10.1007/s12094-019-02143-6